tion. After a median period of 9 months, pre-dialysis plasma oxalate was significantly lower than initially (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02). Conclusion: This methodology can be used to individualize the dialysis prescription of PH patients to prevent oxalosis during the time they are maintained on HD and to reduce risk of oxalate injury to a transplanted kidney.
Introduction
The dicarboxylic acid oxalate is an end product of liver glyoxalate and glycerate metabolism that cannot be further metabolized and is therefore excreted in the urine [1, 2] . Patients with primary hyperoxaluria (PH) have markedly increased oxalate production related to defects in one of at least three genes that code for enzymes important in the metabolic pathways. Since oxalate is primarily eliminated via the kidney, PH patients often develop calcium oxalate kidney stones, nephrocalcinosis, and kidney damage. Once kidney failure ensues, oxalate is progressively retained in the body resulting in systemic soft tissue and bone deposition, often leading to early death from oxalosis. Transplantation as soon as possible after the onset of kidney failure is recommended for this patient group. However, waiting times for suitable donor organs often prolong the time until transplantation can be performed, placing the patient at risk of serious complications of systemic oxalosis. In addition, oxalate accumulated in tissues will pose risk to the transplanted kidney as it is slowly mobilized and excreted following transplantation [3] . Therefore, if a patient with PH must be maintained on dialysis it is important to tailor the prescription so that adequate amounts of oxalate are removed [4] . To minimize risk of systemic oxalate deposition, plasma oxalate should be kept below the levels associated with calcium oxalate supersaturation in plasma, i.e. <30 μmol/l [2] . However, it is recognized that standard 3 times/week hemodialysis (HD) does not achieve sustained levels below this threshold in PH patients unless they have significant residual renal function [5] [6] [7] . Peritoneal dialysis is even less effective in oxalate removal [8] . There is little information about how to manage the dialysis of PH patients with end-stage kidney disease (ESKD), especially those who await transplantation. In this study we measured plasma and dialysate oxalate in PH patients and estimated the amount of oxalate removed. Using this data the frequency and/or duration of HD were adjusted as necessary to exceed the estimated daily oxalate production of a given patient.
Subjects and Methods

Patients and Sample Handling
Patients from the Mayo Clinic Hyperoxaluria Center with a confirmed diagnosis of type 1 PH and ESKD on HD were considered for HD oxalate removal studies. This study was approved by Institutional Review Board of Mayo Clinic. Of 17 available patients, 3 were not included in this report because of lack of followup data after individualization of the dialysis prescription (n = 2), and having undergone a prior liver-only transplantation that corrected the oxalate metabolic defect (n = 1). The remaining 14 patients were diagnosed based on hepatic enzyme analysis conforming AGT deficiency (n = 3) or genetic testing for AGXT mutations (n = 11). Eleven patients receiving pyridoxine remained on stable doses (5-10 mg/kg/day) throughout the study, 2 patients did not take pyridoxine because of no response to it and none had initiation of pyridoxine during this time. Thirteen patients were on high-flux HD with Polyflux Revaclear dialyzer (1.4 m 2 , polyarylethersulfone and polyvinylpyrrolidone membrane; Gambro) which was performed for 3-4 h each session. One female patient was on home HD with a NxStage System One (NxStage Medical, Inc.) performed for 4 h every day. HD prescriptions were adjusted according to the historical oxalate production, mass of oxalate removed, urinary clearance of oxalate and pre-dialysis plasma oxalate.
Blood was sampled at the blood inlet of the dialyzer at the start of dialysis and each hour thereafter. During each 1-hour period, a constant percentage of the spent hemodialysate was collected and mixed, with 1 ml sent for oxalate concentration measurement (Oxalate dialysate ). Oxalate removal was calculated as Oxalate dialysate × Volume dialysate . Kt/V was measured in 9 patients during the dialysis session by an online clearance monitor [9] . Previous pharmacokinetic studies using [ 14 C]-oxalate infusion demonstrated that 94% of the administered load was recovered unchanged in urine during the first 24 h [10] . Similar results were obtained in a cohort of 3 typical cases of PH patients [11] . Thus renal excretion accounts for nearly all oxalate elimination. Therefore, the historical daily oxalate production was estimated by the 24-hour urine oxalate determination of a given patient when the glomerular filtration rate (GFR) was >50 ml/min/1.73 m 2 , since it has been established that renal elimination can no longer keep up with oxalate production once the GFR declines to <40-50 ml/min/1.73 m 2 [12] . In 4 patients, historical oxalate production was not available due to renal failure at initial presentation. Patients with urine output also collected a 24-hour urine within 1 week of the dialysis session to calculate renal excretion of oxalate.
Oxalate Measurement
Plasma and urine oxalate were measured using an enzymatic oxalate oxidase method (Trinity Biotech, Wicklow, Ireland), as previously described [13] . This enzymatic method for plasma [13] and urine [14] was also validated for dialysate fluid. The test is based upon oxalate reduction by oxalate oxidase yielding hydrogen peroxide, which in the presence of peroxidase reacts with an indamine dye. This colored endpoint is measured using a sensitive Beckman Coulter DU800 Spectrophotometer at 590 nm.
For assay validation, fresh and waste (exposed to patients) dialysate fluid was obtained and stored for no more than 12 h at 4 ° C before testing. To evaluate analyte stability, aliquots were prepared and the oxalate values obtained immediately at time zero were compared to those under various storage conditions, including multiple freeze thaw cycles.
Data Analysis
Analyses were completed using the statistical programs JMP ® version 9.0.1 (SAS Institute, Inc.) and Microsoft Excel version 2003 (Microsoft Corp.). All values are expressed as mean ± SEM. Student's t tests were used to compare changes between two groups. Paired t tests were used when comparing changes before and after the treatment. The relationship between Kt/V and reduction rate of plasma oxalate was estimated by simple linear regression. Trends in urine oxalate excretion following transplant were estimated using slopes derived from within-patient linear regression. p values <0.05 were considered to be significant.
Results
Dialysate Oxalate Validation
Precision estimates (CV) ranged from 1.1% at a dialysate oxalate level of 19 μmol/l to 10% at 2 μmol/l. Accuracy, evaluated by spiking a dialysate sample with standard material, was 94-110%. Linearity studies in dialysate fluid yielded a measured/expected oxalate signal of 89-109% over a signal range of 2-66 μmol/l. Samples could be diluted up to eightfold with water. Limit of quantification was set to be 2 μmol/l. Proper treatment of dialysate samples after collection was critical, since in certain patient samples oxalate levels increased over the course of 3 days unless samples were acidified to pH 2.5-3.0 within 4 h. After acidification, samples were stable for a week of collection when maintained refrigerated (4 ° C) or frozen at or below -20 ° C.
Oxalate Removal Kinetics
The average age of the 13 HD patients was 38 ± 19 years. There were 6 males and 7 females. Five patients had evidence of systemic oxalosis after a full examination of bone, heart and retina. Twelve patients had urine output (2,797 ± 1,307 ml/24 h) at the time of study, with an average urinary oxalate excretion of 1.1 ± 0.8 mmol/24 h.
Mean reduction in plasma oxalate was 78.4 ± 7.7% after one HD session, with a mean pre-and post-dialysis plasma oxalate of 70.6 ± 38.4 and 13.3 ± 5.9 μmol/l, respectively. In order to graphically pool data, plasma and dialysate oxalate values were normalized to the pre-dialysis plasma oxalate level. The average profile for all 13 patients ( fig. 1 a) demonstrates that plasma oxalate fell by approximately 50% during the first hour and was about 20% of pre-dialysis levels by hour 4. Dialysate oxalate levels were about one half of the plasma oxalate levels at each time point. Thus, the net rate of oxalate removal progressively fell during dialysis, albeit relatively gradually. As shown in figure 1 b, pooled data from patients at three different blood flow rates suggests that higher rates augment the rate of plasma oxalate fall slightly, although the three curves were not statistically different in this small sample (p = 0.76).
There were 9 patients in whom the measured online Kt/V was 1.52 ± 0.42. Simple linear regression demonstrated a good correlation of Kt/V with the final percent reduction in plasma oxalate (R 2 = 0.55, p = 0.02). However, there was minimal correlation between Kt/V and total oxalate removal by dialysis (R 2 = 0.15, p = 0.29).
Modification of Dialysis Strategy
A sample dialysis oxalate clearance report from patient A is shown in table 1 . In this patient, urine oxalate excretion at the time of study was 0.6 mmol/24 h. The amount removed in 3.5 h of dialysis was 1.73 mmol. The historical oxalate production rate from this patient (when the kidney function was normal) was 1.75 mmol/day, or 12.25 mmol/week, so a minimum of 5-6 dialysis sessions per week would be required for its removal. For the 4 patients whose historical urine oxalate excretion was unavailable, one can estimate that oxalate production is in the range of 2.0-2.5 mmol/day for type 1 PH according to published reports [15] .
Based on the method above, 8 patients performed HD 6 times/week, 2 patients 5 times/week, and 3 patients 3 times/week. The blood flow rate was 300-400 ml/min (average 365 ± 38 ml/min) and dialysate flow rate was 600-800 ml/min (average 769 ± 75 ml/min). Each patient's total oxalate removal, estimated oxalate production, previous and adjusted HD prescriptions as well as plasma oxalate change are listed in table 2 . For the 9 pa- Plasma and dialysate oxalate kinetics. a The average profile of plasma and dialysate change during one dialysis session. Normalized plasma and dialysate oxalate concentrations were calculated by plasma and dialysate oxalate of each hour in proportion to pre-dialysis plasma oxalate. b Influence of blood flow rate on oxalate removal. Dialysate flow rate was 800 ml/min for each measurement. The plasma oxalate levels were slightly lower at a blood flow rate of 400 ml/min (n = 7) compared to 350 ml/min (n = 4) or 300 ml/min (n = 1) (p = 0.76). The analysis of covariance (AN-COVA) was used to compare the slope of different blood flow rate.
tients who had historical urine oxalate excretion data, total oxalate removal by HD and the kidneys exceeded or equaled the estimated oxalate production. The average oxalate removed by HD of all patients was 11.13 ± 6.88 mmol/week. Combined the oxalate removed by HD and urine was 18.34 ± 6.95 mmol/week. Given the estimated weekly historical oxalate generation of 14.04 ± 4.09 mmol/ week, the current HD regimen was efficient enough to overcome endogenous oxalate production. After a median period of 9 (1-29) months individualized HD, predialysis plasma oxalate was significantly lower than the initial values (75.1 ± 33.4 vs. 54.8 ± 46.6 mmol/l, p = 0.02).
Nine patients received transplantation, including one kidney-alone transplant in a patient who was fully pyridoxine responsive, and 8 combined liver-kidney transplant (LKT) after a median period of 6 months (1-27 months) on HD. Except for patient M whose plasma oxalate increased because of a rapid decline in residual renal function (urine oxalate decreased from 1.17 to 0.19 mmol/24 h before transplantation), the other 8 patients' pre-dialysis plasma oxalate before transplantation was 45.4 ± 23.1 μmol/l, which is significantly lower than the initial predialysis plasma oxalate (before the dialysis prescription was individualized) at 86.1 ± 34.7 μmol/l, p < 0.01. Among The blood flow rate was 300 ml/min and dialysate flow rate was 800 ml/min. Oxalate removed through this time interval was calculated by dialysate fluid oxalate × dialysate volume. Total oxalate removed over 3.5 h was 1.73 mmol. 8 patients who underwent LKT, 1 patient's renal graft lost function at 3 months after transplantation because of acute tubular necrosis and started HD again. In the remaining 7 patients, urine oxalate levels dropped gradually and normalized in a median time of 6 months ( fig. 2 ) .
Results of Home Daily HD Using NxStage System
One additional female patient (31 years old) was on home HD. Blood and dialysate flow rates were 390 and 150 ml/min, respectively. Mean pre-dialysis plasma oxalate was 51.25 ± 10.54 μmol/l with a post-dialysis oxalate of 13.60 ± 1.56 μmol/l averaged over two runs (net decrease 82%). Oxalate removed from each session was 1.03 ± 0.20 mmol. A recent 24-hour urine oxalate was 0.56 mmol. Combining the oxalate removed by HD and urine, total oxalate removal was 1.59 ± 0.20 mmol/day. Her historical estimated oxalate production was 1.45 mmol/day, suggesting that for this patient with moderate oxalate production and residual renal oxalate excretion, daily home HD for 4 h was sufficient.
Discussion
Although PH patients produce 3-10 times the normal amount of oxalate, this amount can be efficiently eliminated by well-functioning kidneys. However, since oxalate is largely eliminated by filtration, as GFR falls, plasma oxalate levels progressively rise. Oxalate distributes throughout the extracellular fluid and when its concentration exceeds calcium oxalate supersaturation (about 30 μmol/l at normal ionized calcium concentrations), spontaneous crystallization can occur leading to systemic oxalosis [2] . One major site of deposition is bone, and biopsies of the iliac crest have documented localized bone oxalate levels 300 times normal in PH patients on dialysis. These levels progressively increase with time on dialysis [16] . Clinical consequences include anemia refractory to erythropoiesis-stimulating agents and osteodystrophy resulting in fractures. Oxalate deposition in the myocardium leads to cardiomyopathy and in the conduction system is a cause of fatal arrhythmias. Involvement of multiple organ systems by oxalosis leads to increasing morbidity and death. As oxalate deposits in tissues, blood levels plateau and no longer increase to accurately reflect the increasing total body oxalate burden [5] .
Unfortunately, kidney failure is common in PH. Early studies reported that 50% of PH patients developed ESKD by 15 years of age and 80% by age 30. Recent improvements in the diagnosis and management of PH have increased the median survival without ESKD to 33 years [17] . Our patients developed ESKD at an average age of 37 years, which is in good agreement with these recent reports. Oxalate accumulation in body tissues not only results in significant morbidity and/or death, but gradual mobilization of tissue and bone oxalate stores after kidney transplantation produces hyperoxaluria and places the kidney allograft at risk for oxalate injury over many months or years [18] . Therefore, it is important to develop methods to manage this group of patients when ESKD ensues, including how to effectively dialyze them until transplantation can be performed.
Oxalate is reasonably well removed by dialysis (clearance about 75% that of urea) [19] , as evidenced by the correlation of Kt/V with fall in plasma oxalate levels. Even so, the amount removed in a standard 3-day/week HD regi- Color version available online men cannot keep up with production rates [19] , in part because oxalate is only removed from the blood compartment, and equilibration of plasma oxalate with extravascular compartments like bone is slower. These considerations likely explain the poor correlation of Kt/V with total oxalate removal. Furthermore, as plasma oxalate levels rapidly decline during a dialysis session, the gradient for oxalate diffusion falls, and the amount removed falls with each time period in a given dialysis session ( fig. 1 a) . A considerable rebound also typically occurs as soon as each session of HD is concluded [6] . Thus, more frequent HD sessions are more efficient than longer, less frequent dialysis regimens. Our data suggested that higher blood flow rate resulted in a greater reduction of plasma oxalate, consistent with the results of Illies et al. [6] . Accordingly, a maximal blood flow rate should be applied.
Oxalate production by the liver is markedly increased in all patients with PH, but the degree of overproduction varies substantially from one PH patient to another, in part related to genotype [17, 20] . A method to accurately measure oxalate removal during dialysis is helpful to calculate the appropriate dialysis dose. In this paper we describe a reasonably simple method that employs hourly samples of dialysate and comparison to estimated historical oxalate production of the patient. If unknown, one can estimate that oxalate production is often in the range of 1.5-2.0 mmol/day (types 2 and 3 PH) to 2.0-2.5 mmol/ day (type 1 PH) [15] . [ 14 C]-oxalate tracer methods in a small numbers of PH patients of unknown type previously estimated daily oxalate removal rates 1.1-6.6 mmol/ day/1.73 m 2 when GFR was >45 ml/min [11] . Pyridoxine responsiveness should also be considered. The genotype G170R for example confers complete or partial response to pyridoxine [20] . A pre-dialysis plasma oxalate well below the predicted calcium oxalate supersaturation threshold of 30 μmol/l would also be reassuring confirmation that the patient is receiving adequate oxalate removal [2] .
Although we measured plasma and dialysate oxalate hourly during the treatment, in order to assess the kinetics of oxalate removal, in practice this protocol might be simplified. Determination oxalate in the hourly or total hemodialysate removed and pre-and post-dialysis plasma oxalate could suffice if the only question is how much oxalate was being removed. However, the hourly plasma and dialysate oxalate values provide insight regarding the effect adding of additional time per dialysis session might have. It is also important to measure 24-hour urine oxalate elimination, since in some patients significant amounts can be eliminated by the kidneys for a long period time on dialysis. It is also necessary to modify the dialysis prescription if GFR declines. In our subgroup of patients with residual urine output, urinary oxalate elimination accounted for a significant amount of total oxalate removal (10-66%) that was helpful for managing the patients. Thus all measures should be taken to maintain this urinary excretion, such as avoidance of intravascular volume contraction, including that caused by hypotension and aggressive dialysis ultrafiltration. Indeed, among PH patients who maintain urine output despite ESKD, administration of intravenous fluid during each dialysis session can be helpful.
Based on these measurements, the total amount of oxalate eliminated in this patient group was sufficient to equal estimated endogenous oxalate production. This may be in part due to the highly permeable membrane we used, since previous studies suggested that dialysis oxalate removal may be increased by the use of a dialyzer with a larger surface and a high-flux membrane [7] . After the individualized HD, pre-dialysis plasma oxalate significantly decreased and urine oxalate dropped faster after liver transplantation. In a previous report of PH patients after LKT in 2001 [21] , the median time required until urine oxalate reached normal range was 14 months, which was somewhat longer than the time (6 months) in our study (p = 0.11 by Wilcoxon test, patients' data obtained from DSM). Thus, individualized intense dialysis regimens in PH patients cannot only reduce risk for systemic deposition of oxalate during dialysis, but also may shorten the time required for resolution of hyperoxaluria following liver transplantation and improve transplantation outcome. Dialysis is not an ideal long-term treatment for PH patients with ESKD, especially when patients lose urine output and 5-6 treatments per week are necessary. Nevertheless, appropriate adjustment of dialysis and this intensified regimen should still be employed as a bridge to liver and kidney transplantation so that accumulation of oxalate in tissues will be minimized, and exposure of the transplanted kidney to the damaging effects of hyperoxaluria avoided to the greatest extent possible [3, 18] .
The NxStage system which uses sterile dialysis fluid in bags and a single extracorporeal circuit cartridge with a polysulfone dialysis is a generally safe and efficient method of dialysis [22, 23] . The 1 patient who used NxStage System in our study received sufficient oxalate removal for her relatively low production rates, even though oxalate removed by NxStage was only 1.03 ± 0.20 mmol/l, significantly lower than the patients using a Polyflux Revaclear dialyzer. This individual also had some residual renal clearance of oxalate (0.6 mmol/day). This is probably due to the relatively low dialysate flow rates (150 ml/ min) and small volume of dialysate employed in this home system. Whether or not patients with higher oxalate production rates can be safely managed by NxStage dialysis remains to be assessed.
This study also demonstrates that oxalate can be accurately measured in dialysate using an oxalate oxidasebased assay adapted from a sensitive plasma method. Sample handling is important in order to achieve accurate results. In particular, acidification within 4 h is essential to prevent non-enzymatic production of oxalate, as has been well described during measurement of oxalate in plasma [13] . In addition, samples should be maintained frozen (-20 ° C) or refrigerated (4 ° C) after acidification. Frozen, non-acidified samples can be transported or stored for 3 days prior to acidification with an expected signal change below 15%.
In conclusion, we have analytically validated a method to accurately measure oxalate in HD, and provide an example how this can be applied to patients with hyperoxaluria. Dialysis regimens of PH patients on HD should be adjusted based on plasma, dialysate oxalate and urine oxalate values to make sure that there is enough oxalate removed to minimize the risk of systemic oxalosis.
